GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Guardion Health Sciences Inc (STU:0QTA) » Definitions » Debt-to-Revenue

Guardion Health Sciences (STU:0QTA) Debt-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Guardion Health Sciences Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Guardion Health Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. Guardion Health Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. Guardion Health Sciences's annualized Revenue for the quarter that ended in Dec. 2023 was €10.77 Mil. Guardion Health Sciences's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.00.


Guardion Health Sciences Debt-to-Revenue Historical Data

The historical data trend for Guardion Health Sciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardion Health Sciences Debt-to-Revenue Chart

Guardion Health Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only 0.65 0.23 - - -

Guardion Health Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Guardion Health Sciences's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Guardion Health Sciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guardion Health Sciences's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Guardion Health Sciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Guardion Health Sciences's Debt-to-Revenue falls into.



Guardion Health Sciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Guardion Health Sciences's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 11.232
=0.00

Guardion Health Sciences's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 10.768
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Guardion Health Sciences Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Guardion Health Sciences's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Guardion Health Sciences (STU:0QTA) Business Description

Traded in Other Exchanges
Address
2925 Richmond Avenue, Suite 1200, Houston, TX, USA, 77098
Guardion Health Sciences Inc is a specialty health sciences company formed to develop, formulate and distribute condition-specific medical foods with an initial medical food product. The company's Medical Foods include Lumega-Z and GlaucoCetin; Medical Devices include Mapcat SF, VectorVision, CSV-1000 and CSV-2000; Nutraceuticals include ImmuneSF.

Guardion Health Sciences (STU:0QTA) Headlines

No Headlines